MX2007014831A - Derivados de quinolina como antagonistas de neurocinina-3. - Google Patents

Derivados de quinolina como antagonistas de neurocinina-3.

Info

Publication number
MX2007014831A
MX2007014831A MX2007014831A MX2007014831A MX2007014831A MX 2007014831 A MX2007014831 A MX 2007014831A MX 2007014831 A MX2007014831 A MX 2007014831A MX 2007014831 A MX2007014831 A MX 2007014831A MX 2007014831 A MX2007014831 A MX 2007014831A
Authority
MX
Mexico
Prior art keywords
alkyl
pharmaceutically acceptable
cyanomethyl
phenyl
disease
Prior art date
Application number
MX2007014831A
Other languages
English (en)
Spanish (es)
Inventor
Yan Li
Thomas R Simpson
James Kang
S Jeffrey Albert
Cristobal Alhambra
M Gerard Koether
M James Woods
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2007014831A publication Critical patent/MX2007014831A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2007014831A 2005-06-03 2006-05-30 Derivados de quinolina como antagonistas de neurocinina-3. MX2007014831A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68741805P 2005-06-03 2005-06-03
PCT/SE2006/000630 WO2006130080A2 (en) 2005-06-03 2006-05-30 Quinoline derivatives as nk3 anatgonists

Publications (1)

Publication Number Publication Date
MX2007014831A true MX2007014831A (es) 2008-02-15

Family

ID=37482086

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007014831A MX2007014831A (es) 2005-06-03 2006-05-30 Derivados de quinolina como antagonistas de neurocinina-3.

Country Status (11)

Country Link
US (1) US20080200500A1 (cg-RX-API-DMAC7.html)
EP (1) EP1891012A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008542367A (cg-RX-API-DMAC7.html)
KR (1) KR20080016591A (cg-RX-API-DMAC7.html)
CN (1) CN101189211A (cg-RX-API-DMAC7.html)
AU (1) AU2006253054A1 (cg-RX-API-DMAC7.html)
CA (1) CA2611060A1 (cg-RX-API-DMAC7.html)
IL (1) IL187410A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007014831A (cg-RX-API-DMAC7.html)
NO (1) NO20080033L (cg-RX-API-DMAC7.html)
WO (1) WO2006130080A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
AR072198A1 (es) 2008-06-23 2010-08-11 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
AR073891A1 (es) 2008-10-20 2010-12-09 Lundbeck & Co As H Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
US10314835B2 (en) 2014-06-25 2019-06-11 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
KR20160069683A (ko) 2014-12-09 2016-06-17 백찬욱 콤비보트 및 그 제작 방법
US11458129B2 (en) 2017-11-02 2022-10-04 California Institute Of Technology Neurokinin antagonists and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531458T2 (de) * 1994-05-27 2004-08-05 Glaxosmithkline S.P.A. Chinolinderivate als tachykinin nk3 rezeptor antagonisten
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
AR004735A1 (es) * 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
CN1264378A (zh) * 1997-05-23 2000-08-23 史密丝克莱恩比彻姆股份公司 作为nk-2和nk-3受体拮抗剂的喹啉-4-甲酰胺衍生物
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
JP2002530377A (ja) * 1998-11-20 2002-09-17 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ Nk−3およびnk−2受容体アンタゴニストとしてのキノリン−4−カルボキシアミド誘導体
EP1385839B1 (en) * 2001-04-11 2006-02-22 GlaxoSmithKline S.p.A. 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US20080280949A1 (en) * 2005-08-11 2008-11-13 Astrazeneca Ab Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
AR058051A1 (es) * 2005-09-21 2008-01-23 Astrazeneca Ab Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas.
US20090054445A1 (en) * 2006-01-27 2009-02-26 Astrazeneca Ab Amide Substituted Quinolines

Also Published As

Publication number Publication date
AU2006253054A1 (en) 2006-12-07
WO2006130080A3 (en) 2007-01-25
NO20080033L (no) 2008-01-03
CA2611060A1 (en) 2006-12-07
CN101189211A (zh) 2008-05-28
US20080200500A1 (en) 2008-08-21
EP1891012A2 (en) 2008-02-27
KR20080016591A (ko) 2008-02-21
IL187410A0 (en) 2008-02-09
JP2008542367A (ja) 2008-11-27
WO2006130080A2 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
US8071621B2 (en) Alkylsulphonamide quinolines
JP2004525184A (ja) Nk−3およびnk−2受容体アンタゴニストとしての3−置換キノリン−4−カルボキサミド誘導体
CN101189211A (zh) 作为nk3拮抗剂的喹啉衍生物
JP2008542367A5 (cg-RX-API-DMAC7.html)
US20080306110A1 (en) Alkylnitrile Quinolines as Nk-3 Receptor Ligands
MX2007015607A (es) Esteres de quinolin 3-sulfonato como moduladores del receptor de nk3.
US20080200504A1 (en) Amide Alkyl Pyridiyl Quinolines as Nk3 Receptor Modulators
US20080280949A1 (en) Oxopyridyl Quinoline Amides as Nk3 Receptor Modulators
CN101370782A (zh) 烷基磺酰胺喹啉
CN101268052A (zh) 作为nk-3受体配体的n-氧代-杂环和n-氧代-烷基喹啉-4-甲酰胺
EP1915361A1 (en) Alkylpyridyl quinolines as nk3 receptor modulators
KR20090122253A (ko) 퀴놀린 유도체, 이를 포함하는 제약 조성물, 및 중추신경계 및 말초 질환의 치료에서의 이의 용도
HK1121759B (en) Alkylsulphonamide quinolines

Legal Events

Date Code Title Description
FA Abandonment or withdrawal